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Summary Seven patients with small volume ovarian carcinoma, remaining after conventional therapy with
surgery and a platinum containing chemotherapy regimen, were treated with intraperitoneal monoclonal
antibody guided radiotherapy. 100mCi'3' I conjugated to 10mg of monoclonal antibody were injected i.p. in
2,000ml peritoneal dialysis fluid. Patients were evaluated 3 months later; 3 had clinical progressive disease
while third look laparotomy demonstrated progressive disease in 3 of the remaining 4 patients. The seventh
patient did not have a third look laparotomy and is currently inevaluable for response.
Five patients with recurrent malignant ascites not controlled by diuretics or repeated paracentesis were
similarly treated with 75-170mCi13' I conjugated to 10mg monoclonal antibody. In three patients the ascites
was controlled for a mean of 4 months. One patient died too early to assess the control of his ascites but
tumour cells disappeared from the ascitic fluid after therapy. In the patient whose ascites was not controlled,
a subpopulation of antigen-negative tumour cells was demonstrated. This study was unable to demonstrate a
therapeutic benefit for i.p. injected monoclonal antibody guided radiotherapy for solid intraperitoneal tumour
but suggests that it may be capable of controlling the accumulation of antigen positive malignant ascites.
Ovarian carcinoma is the most common cause of death from
gynaecological cancer and the third most common of all
cancers in women. In England and Wales, over 3,700 women
die each year and 4,000 new cases are diagnosed (Toms et
al., 1981). The majority of patients with ovarian carcinoma,
therefore, die of their disease. While mortality rates for
carcinoma of the cervix and uterus have dropped over the
last 30 years, the mortality rate for carcinoma of the ovary
has risen (Osmond et al., 1983).
The cornerstone of current therapy is surgery, as prognosis
is most strongly related to volume of disease remaining after
a debulking operation (Griffiths et al., 1979). While high
response rates to multidrug regimens have been reported
(Slevin, 1986), no improvement in long term survival has yet
been achieved. Patients with ovarian cancer may continue to
relapse and die of disease many years after achieving com-
plete remission (Neijt et al., 1986). When patients relapse
after chemotherapy, the options are extremely limited. The
emergence of chemoresistance in previously chemosensitive
tumours has been well documented both in vivo (Friedlander
et al., 1985) and in vitro (Wilson & Neal, 1981) and no long
term benefit is available from further chemotherapy. The
place of abdomino-pelvic radiotherapy at this point is also
unclear (Dembo et al., 1979). There is a clear need for
further effective therapeutic modalities in this disease.
The success of monoclonal antibodies, labelled with a
radioisotope, to detect ovarian cancer by immunoscinti-
graphy (Epenetos et al., 1982, 1985; Patiesky et al., 1985),
suggested that monoclonal antibody targetted therapy could
be possible. However studies of antibody uptake by tumour
after intravenous injection, suggested that insufficient dis-
crimination between tumour and blood as well as low
absolute levels of uptake occurred (Epenetos et al., 1986).
Therefore, a regional, intraperitoneal approach to ovarian
cancer seemed logical for many reasons. While over 80% of
patients have disease outside the pelvis at presentation, over
75% have disease confined to the peritoneal cavity
(Shepherd, 1985). Large i.p./i.v. concentration advantages
have been demonstrated when chemotherapy has been given
intraperitoneally rather than intravenously (Myers & Collins,
1983) and it has been shown that i.p. injected albumin can
penetrate tissue to a depth in excess of 1 cm (Dedrick, 1985).
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Early, empirical studies were encouraging, however, quanti-
tative studies on the uptake of i.p. injected monoclonal
antibodies into solid tumour and ascites were equivocal
when solid tumour was considered (Hammersmith Oncol.
Gp. & ICRF, 1984; Epenetos, 1986; Ward et al., 1987).
Uptake of i.p. injected monoclonal antibody conjugates
into solid tumour was shown to vary markedly both within
and between patients, however, when ascites cells were
considered, consistently greater uptake and large tumour cell:
normal tissue or blood ratios were demonstrated (Ward et
al., 1986; Lawson et al., 1986).
It was therefore decided to perform separate studies of i.p.
1311 monoclonal antibody therapy in patients with ovarian
cancer, recurrent or persistent after conventional therapy,
and in patients with recurrent malignant ascites which was
not controlled by paracentesis and/or diuretics.
Materials and methods
Patients
Patients with ovarian cancer without ascites had failed
conventional therapy consisting of radical debulking surgery
and platinum containing chemotherapy. All patients were
referred after second look laparotomy (Table I) where
further debulking to less than two centimetres disease and
full documentation of site and size of tumour nodules was
carried out.
Patients referred for treatment of recurrent ascites were a
heterogeneous group. All patients had reaccumulation of
ascites within 6 weeks of paracentesis and, in all but 2 (Cases
9 and 12), despite spironolactone orally (Table II).
Patients were treated after full informed consent had been
obtained and these studies were approved, in advance, by the
Ethical Committee of St. Bartholomew's Hospital.
Monoclonal antibodies
HMFG2 HMFG2 (Taylor-Papadimitriou et al., 1981) is an
IgG1 murine monoclonal antibody directed against an anti-
gen found on a high molecular weight glycoprotein differen-
tially expressed by malignant cells. This antigen is found in
the majority of ovarian carcinomas and also in breast,
thyroid and gut adenocarcinomas and differentiated meso-
theliomas.
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Table I Ovarian cancer patients treated by i.p. '31I-HMFG2
57 mod. diff. serous
cystadenocarcinoma
44 mod. diff. serous
cystadenocarcinoma
58 well diff. serous
cystadenocarcinoma
mod. diff. serous
cystadenocarcinoma
mod. diff. serous
cystadenocarcinoma
mod. diff. serous
cystadenocarcinoma
serous
cystadenocarcinoma
Disease statusa
<1 cm3
diffuse
<1 cm3
diffuse spread
Microscopic
only
<2cm3
diffuse spread
<1 cm3
diffuse spread
<1 cm3
diffuse spread
<2cm3
Previous therapyb
JM8
cisplatin/JM8
Radiotherapy
chlorambucil
cisplatin
JM8
JM8
Ifosfamide
JM8
JM8
Antibody 131I
used activity
HMFG2 100mCi
HMFG2 100mCi
HMFG2 100mCi
HMFG2 I00mCi
HMFG2 100mCi
HMFG2 100mCi
HMFG2 150mCi
aAssessed at second look laparotomy within 3 months of radiolabelled monoclonal activity unless clinically progressive disease;
bAll patients had primary debulking surgery.
Table II Recurrent ascites patients treated by 1311 monoclonal antibody
Antibody 131I
Patient no. Age Diagnosis Disease status Previous therapy used activity
8 77 Ca colon Ascites and bulky Surgery AUA1 75mCi
tumour
9 66 Ca colon Ascites and bulky Surgery AUAI 170mCi
tumour
10 59 Ca ovary Ascites and bulky Surgery HMFG2 150mCi
tumour chemotherapy
11 59 Papillary Ascites and bulky Surgery HMFG2 100mCi
peritoneal tumour
mesothelioma
12 49 Ca ovary Ascites and <1cm3 Surgery HMFG2 100mCi
tumour chemotherapy
AUAI AUA 1 (Arklie, 1981) defines a small glycoprotein
antigen expressed on ovarian and gut adenocarcinomas.
The antigens defined by both of these monoclonal anti-
bodies are detectable on the luminal surface of the epi-
thelium of normal tissue (lactating breast, ovary, fallopian
tube for HMFG2; gut for AUAI), but such expression is
minimal.
Antibodies used were produced in bulk by the Cell
Production Unit, ICRF Clare Hall, purified by affinity
chromatography on Protein A-Sepharose and stored, frozen
in citrate buffer.
Iodination of antibodies
Antibodies were conjugated to 1311 by the N-bromo-
succinimide method. This technique has been shown to
reliably result in iodination efficiencies of 95% with no loss
of antibody reactivity. Because of the high iodination
efficiency, no separation of conjugate and free iodine was
necessary. Antibody-radioiodine conjugates were used within
2h of synthesis as radiolysis of antibody has been demon-
strated to occur by 20h (Mather & Ward, 1987). Activity of
iodinated antibody ranged from 7-17mCimg- .
Demonstration of antigen expression
Solid tumour tissue, removed at laparotomy was examined
by the indirect immunoperoxidase technique (Polak & Van
Noorden, 1983) for expression of these tumour associated
antigens on the surface of tumour cells.
Ascites cells, obtained at paracentesis were examined by
immunofluorescence for the presence of the target antigen.
Assessment of immunofluorescence status was by direct
fluorescence microscopy and by fluorescence activated cell
sorting, both methods compared to a negative control anti-
body of the same subclass (UJ13A) Allan et al. (1983)
(Figures I & 2).
Delivery of antibody
Twenty-four hours prior to treatment, a thyroid blocking
regimen of 120mg potassium iodide p.o. daily was begun
and continued for 4 weeks.
In 4 patients treated after second look laparotomy, a
Hickman cannula had been inserted into the peritoneal
cavity at surgery and patency maintained by heparinized
saline flushing. In the other patients, a 14G Wallace IV
Cannula was inserted, under sterile conditions under local
anaesthetic, directly into the peritoneal cavity. Previous
studies using this technique had demonstrated uniform peri-
toneal distribution of antibody conjugate as assessed by
radioimmunoscintigraphy immediately after instillation
(Ward et al., 1987).
Fifteen hundred ml of peritoneal dialysis fluid (CAPD2 -
Frisenius, FRG) was instilled, the system tested for leaks
and the abdomen examined for even distribution of fluid. In
those patients with ascites, the ascites was drained over 4-
96h prior to therapy and no further fluid instilled. It has
been demonstrated that a volume of 1,500-2,000 ml is
required to adequately distribute intraperitoneally injected
substances (Dunnick et al., 1979). The antibody was, there-
fore, then instilled in a further 500ml fluid and the vial
checked to ensure that all antibody was delivered.
At no time, either in the iodination procedure or the
delivery need the radiolabel be handled unshielded.
Pharmacokinetics
Total body counts were made at 6h, 18 h and then daily
using a hand held dose rate meter and, when activity was
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Patient no. Age Histopathology
2
3
4
5
54
74
55
43
6
7
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sufficiently low, this was checked by formal whole body
counting. Patients were allowed home after whole body
activity was below 30mCi.
A sample of blood was also drawn at these times and
escape of activity into the blood assessed, assuming a blood
volume of 80mgkg- 1 (Ganong, 1985).
Follow up
Prior to treatment, baseline levels of haematological indices
and kidney, liver and thyroid function were obtained. These
were repeated at regular intervals (fortnightly for haemato-
logical tests, monthly otherwise).
For solid tumour patients with non-evaluable disease,
third look laparotomy was performed at least 3 months after
treatment. This involved close inspection of all peritoneal
surfaces, peritoneal washings and biopsies. For ascites
patients, evaluation of therapeutic efficacy was by serial
clinical examinations and the requirements for further para-
centesis.
Results
Efficacy
Treatment of solid ovarian cancer Three months after i.p.
instillation of 100mCi1311 conjugated to 10mg HMFG2,
three patients (Nos. 1, 5 and 7) had evaluable progressive
disease and two have subsequently died. Three patients had
third look laparotomy performed and, in all, progressive
disease was demonstrated and histologically confirmed. One
patient refused third look laparotomy and is currently free of
disease 13 months later.
In one patient (Patient 4), isolated tumour foci, noted at
the previous laparotomy on the bowel serosa, were seen to
have regressed, while new disease at the hepatic flexure had
appeared. There was no overall benefit to the patient.
In Patient 2, a fine intraperitoneal adhesion reaction was
seen, this patient subsequently developed small bowel
obstruction which was managed conservatively. This was not
seen in the other two patients at third look laparotomy.
Figure 1 HMFG2 antigen expression demonstrated on a clump
of ascites cells by the immunofluorescence technique ( x 400).
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Figure 2 HMFG2 antigen expression demonstrated on a popu-
lation of ascites cells by fluorescence activated cell sorting. Note
that the fluorescence profile of the cells after incubation with
UJ13A is identical to that seen when cells are incubated in PBS
alone.
Treatment of recurrent ascites Patient 8 suffered no ill
effects from treatment and his whole body activity had
decreased sufficiently for him to be discharged home by 7
days after injection. By 4 weeks after discharge, his ascites
had cleared completely on clinical examination, revealing
large intra abdominal tumour masses which remained
unchanged. In this period, his girth decreased from 107cm
to 94cm, his appetite and level of activity increased and his
ascites did not recur. He died with progressive solid masses
in his abdomen four months after intraperitoneal therapy
without recurrence of his ascites.
Patient 9 presented with a rapid onset ascites one month
before intraperitoneal treatment. At laparotomy he had
extensive disease (Stage IV), and his ascites recurred within 2
weeks of surgery. Nine litres of ascites fluid were removed in
the 48 h prior to instillation of the conjugated antibody.
Three days after antibody was instilled he became severely
hypovoaemic with oliguria and hypotension. He was resusci-
tated by fluid replacement but complained of severe dyspha-
gia preventing intake of all solids. Serum analysis and
cardiac enzyme levels were normal, as was his ECG. Seven
days after intraperitoneal treatment, a further hypovolaemic
crisis occurred, from which he did not recover. Ascites
removed at this time demonstrated complete absence of
tumour cells. Complete drainage paracentesis was not per-
formed on subsequent patients.
Patient 10 had recurrent ascites from carcinoma of the
ovary previously treated with intensive chemotherapy (high
dose cyclophosphamide and cisplatin). Both her primary
tumour and ascites cells expressed the HMFG2 antigen and
this antibody was used for therapy. Seven hours after
injection of the antibody, ascites were withdrawn and
autoradiography of the cell pellet demonstrated specific
uptake of isotope by tumour cells. Some clumps of tumour
cells, however, were free of activity (Figure 3). Her ascites
did not resolve and a further ascites sample taken at 18 days
after injection showed numerous tumour cells which were
HMFG2 negative (Figure 4). Autoradiography of this cell
pellet demonstrated no retained activity. She also suffered
severe dysphagia. Serum amylase and cardiac enzyme levels
were normal as was an ECG. Barium swallow and
oesophagoscopy demonstrated reflux oesophagitis and hiatus
hernia. Her ascites recurred over the following 2 months and
required drainage. She died of disease at 3 months after
intraperitoneal therapy. Autopsy revealed massive dissemi-
nated intra abdominal tumour.
Patient 11 suffered from Stage IV mesothelioma. The
histology of the tumour was of a well differentiated papillary
pattern with expression of the HMFG2 antigen. Following
injection of conjugated HMFG2, he suffered no ill effects,
however a week later he was readmitted suffering a mild
dysphagia which settled spontaneously. His ascites regressed
with a decrease in girth of 5cm. His weight decreased by
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Figure 3 Autoradiography of cell pellet of Patient 10 7h after
i.p. injection of HMFG2-1311 conjugate. Note localization of
isotope activity while some clumps of tumour cells (arrowed) are
free of isotope (Haematoxylin counterstain x 25).
C.)
')
a)
._
.
100
10
Figure 4 Cell pellet from the same patient at 18 days. Note
absence of tumour cells which were shown to be HMFG2
antigen negative. No isotope activity could be demonstrated by
autoradiography. (H & E x40).
5kg, and his attending physician reported an increase in
muscle bulk. His serum albumin rose from 20g1-1 to
30g1-1. Four months after treatment his ascites recurred
and he died of progressive disease shortly thereafter.
Patient 12 had recurrent ascites from a carcinoma of the
ovary. The HMFG2 antigen was expressed on both the
ascites cells and in her primary tumour specimens. She
suffered no ill effects of treatment and her ascites regressed
over the following 6 weeks. The ascites recurred 4 months
later.
Side effects
A transitory drop in all haematological indices to 80% of
pretreatment values was seen 4-8 weeks after treatment. In
one patient (Patient 10), a prolonged thrombocytopenia was
seen (platelet count nadir of 17xl091-1). Platelet support
was not required.
Three patients (Patients 9, 10, 11) suffered from dysphagia
beginning 3-4 days after therapy. In Patients 9 and 10, this
was severe and not relieved by antacid and H2 blockers. An
hiatus hernia was demonstrated radiologically in Patient 10
but no cause was found in Patient 9 before he died of
disease.
The majority of patients complained of nausea and 'feeling
unwell' for 36h after antibody injection, but no treatment
was required, no vomiting occurred and all symptoms spon-
taneously resolved.
Pharmacokinetics
Pharmacokinetics of the injected radioisotope were analysed
separately in the two groups.
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Figure 5 Whole body activity and whole blood activity in
patients (a) with small volume tumour without ascites, and (b)
with ascites. From these curves, the whole body effective half life
of radioiodine were measured as (a) 34h and (b) 50h.
Ovarian cancer patients without ascites Following injection,
whole body activity declined exponentially with a half life of
34h. Maximum blood levels were 18+5% total activity and
were seen at 60h (Figure 5a).
Patients with malignant ascites In these patients, whole
body activity also declined exponentially, with a mean half
life of 50h. Maximum blood levels were 6+ 1% total activity
and these were seen at 40-80h (Figure Sb).
Discussion
In this study, 7 patients with small volume, recurrent ovarian
carcinoma were treated with HMFG2 conjugated 1311. All
patients' tumours were shown to express the HMFG2 anti-
gen. Although previous tracer dose studies (Ward et al.,
1987) suggested that this therapy might not be successful, it
was important that a small, well documented study be
performed to ensure that more favourable microdosimetry
was not being overlooked. Although some individual tumour
deposits in one patient were shown to regress, in no patient
was there overall regression of disease.
In the treatment of malignant ascites however, three of
four assessable patients had resolution of their ascites such
that further paracentesis or therapy was not required. These
early results are interesting and need to be confirmed in
larger studies. Further studies to compare specific to non-
specific antibody and with other interperitoneal therapies
including the instillation of antitumour agents (Ostrowski &
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Halsall, 1982), antibiotics (Anderson et al., 1974) or radio-
active isotopes of phosphorus or gold (Ariel et al., 1966;
Dybicki et al., 1959) will be needed.
In the patient whose treatment failed, a population of
antigen negative cells which failed to localize the antibody
conjugate was demonstrated. Epenetos (Personal communi-
cation) recently experienced a similar case, where the antigen
negative cell population was shown to express an alternative
tumour associated antigen and the patient was successfully
retreated. In this instance, unfortunately, no such alternative
tumour associated antigen expression was demonstrated.
This case, however, does serve as an important negative
control and demonstrates that the resolution of ascites seen
in the other patients was dependent on the specific activity of
the antibody. The rapid clearance of tumour cells from the
ascites of Patient 9 would support this.
The death of Patient 9 was considered to be due to
hypovolaemic shock related to fluid shifts from his large
volume paracentesis and poor fluid intake at the time. He
had no symptoms suggesting localized toxicity and the
pharmacokinetic data provided by him did not differ from
his peers.
When the clearance of antibody conjugate from the body
was investigated, it was seen that patients with malignant
ascites had a much slower clearance of radioactivity than
those with solid tumours. This was reflected in the maximum
serum levels achieved and the time at which they occurred.
These data suggest that the monoclonal antibody conjugate
was being trapped by the high concentration of antigen
present in the ascites and further supports the specific nature
of this antitumour therapy.
There have been several case reports of successful radio-
immunotherapy for solid intraperitoneal deposits described.
However, these patients comprise the first series reported
where all patients were objectively evaluated using third look
laparotomy if appropriate. Unfortunately, the results have
not demonstrated therapeutic efficacy for intraperitoneal
monoclonal antibody guided therapy in the treatment of
solid ovarian cancer deposits. For palliative treatment of
malignant ascites, however, such monoclonal antibody
therapy may have therapeutic potential.
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